Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology

Reuters

08/04

<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology

Medicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array $(MNA)$ delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556981386"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556981386\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556981386?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556981386","market":"nz","top_or_hot":-1,"title":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array <a href=\"https://laohu8.com/S/MNA\">$(MNA)$</a> delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-04 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array <a href=\"https://laohu8.com/S/MNA\">$(MNA)$</a> delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCX","symbol_name":"Medicus Pharma Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL34xW2N:1","article_id":"2556981386","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556981386","pubTimestamp":1754307065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology. Medicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array  delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCX":"Medicus Pharma Ltd.","BK4139":"生物科技"},"translate_title":"Medicus Pharma Ltd.宣布利用创新微针阵列技术进行热稳定mRNA疫苗的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCX":0.9},"content_text":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n    \n\nMedicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array $(MNA)$ delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}